Menu
Sign In Pricing Add Podcast

BackTable Urology

Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1184.079 - 1203.234 Dr. Andrea Apolo

And this includes positive margins and positive lymph nodes, which, you know, it's kind of special that we included positive margins. Or they did not receive cisplatinibase neoadjuvant therapy but have a T3 or greater muscle invasive disease or positive lymph nodes or positive margins.

0
💬 0

Comments

There are no comments yet.

Log in to comment.